| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JC.2011-1054 |
| P953 | full work available at URL | http://press.endocrine.org/doi/full/10.1210/jc.2011-1054 |
| https://academic.oup.com/jcem/article-pdf/97/2/E173/10413942/jcemE173.pdf | ||
| https://doi.org/10.1210/jc.2011-1054 | ||
| https://europepmc.org/articles/PMC3275354 | ||
| P932 | PMC publication ID | 3275354 |
| P698 | PubMed publication ID | 22090271 |
| P50 | author | Dingxie Liu | Q55459885 |
| P2093 | author name string | Mingzhao Xing | |
| Ruixin Liu | |||
| P2860 | cites work | BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications | Q37709675 |
| Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer | Q37767709 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. | Q39586177 | ||
| The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. | Q39779440 | ||
| Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. | Q40079043 | ||
| The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway | Q40112927 | ||
| Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells | Q40328451 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. | Q43251079 | ||
| Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest | Q43913559 | ||
| Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers | Q46585245 | ||
| Genetic-targeted therapy of thyroid cancer: a real promise. | Q54729328 | ||
| Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer | Q79819385 | ||
| BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma | Q80172894 | ||
| Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer | Q81566849 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy | Q24645466 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo | Q28476362 | ||
| Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation | Q28638584 | ||
| Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 | ||
| Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications | Q33480990 | ||
| Multiple functions of p27(Kip1) and its alterations in tumor cells: a review | Q33853215 | ||
| The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway | Q34758583 | ||
| Motesanib diphosphate in progressive differentiated thyroid cancer. | Q34791480 | ||
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| Akt inhibitors in clinical development for the treatment of cancer | Q35628576 | ||
| The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204) | Q36130527 | ||
| Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia | Q36746834 | ||
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 | ||
| BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications | Q36972859 | ||
| Recent advances in molecular biology of thyroid cancer and their clinical implications | Q37041330 | ||
| Phase II trial of sorafenib in metastatic thyroid cancer | Q37158278 | ||
| Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin | Q37373348 | ||
| Perifosine: update on a novel Akt inhibitor. | Q37393008 | ||
| The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways | Q37420518 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thyroid cancer | Q826522 |
| MK-2206 | Q25100065 | ||
| P304 | page(s) | E173-82 | |
| P577 | publication date | 2011-11-16 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells | |
| The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells | |||
| P478 | volume | 97 |
| Q46040368 | AKT1 Inhibitory DNAzymes Inhibit Cell Proliferation and Migration of Thyroid Cancer Cells |
| Q39089252 | Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E. |
| Q35104869 | Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer |
| Q37168778 | Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer |
| Q35132767 | Disruption of mutated BRAF signaling modulates thyroid cancer phenotype |
| Q42370484 | Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells |
| Q37635839 | Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q36799818 | FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma |
| Q38128097 | Genetics and epigenetics of sporadic thyroid cancer |
| Q33601377 | In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor |
| Q37240206 | MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth |
| Q48273491 | MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. |
| Q36634818 | Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates |
| Q34329018 | Molecular pathogenesis and mechanisms of thyroid cancer |
| Q39245623 | Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro |
| Q35381593 | New therapies for dedifferentiated papillary thyroid cancer |
| Q41628138 | PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells |
| Q38644584 | PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas |
| Q39246432 | Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines |
| Q37689286 | Recent Advances on Small-Molecule Survivin Inhibitors. |
| Q38546474 | Selective use of vandetanib in the treatment of thyroid cancer |
| Q37625891 | Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. |
| Q54111658 | The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib |
| Q39326839 | Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets |
| Q33570056 | Update: the status of clinical trials with kinase inhibitors in thyroid cancer |
Search more.